Site Specific and Global Epigenomic Editing

Principles and Applications

1st Edition, Volume 33 - November 1, 2024
Editors: Feng C Zhou, Trygve Tollefsbol
Language: English
Paperback ISBN:
9 7 8 - 0 - 1 2 - 8 1 9 3 9 8 - 3
eBook ISBN:
9 7 8 - 0 - 1 2 - 8 1 9 3 9 9 - 0

Site Specific and Global Epigenomic Editing: Principles and Applications, Volume 33 highlights the expanding role that epigenetics plays in pathogenesis, the full range of sites… Read more

Purchase options

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code is needed.

Institutional subscription on ScienceDirect

Request a sales quote

Site Specific and Global Epigenomic Editing: Principles and Applications, Volume 33 highlights the expanding role that epigenetics plays in pathogenesis, the full range of sites for possible epigenetic modification, and the potential to target these sites to modulate disease progression. The book answers key questions, including which of the hundreds of epigenomic marks and features are relevant, and which are likely to serve a role in regulating gene expression, cell behavior and phenotypic outcomes. This volume is the first to provide a thorough, conceptual introduction to epigenetic regulation and a thorough accounting of sites for possible epigenetic edits and disease modulation.

Included protocols and applied case studies examine early disease targets and likely pathways of therapeutic significance while also outlining common challenges in the field. The book addresses its topic in a comprehensive, but accessible manner, highlighting practical tools and burning questions remaining in the field to enable fresh research.

Part I EPIGENETICS AND EPIGENOMICS

1. Epigenetic editing: Progress and Challenges

2. Epigenetic dynamics: Normal progression and abnormal alteration

3. Epigenomic landscape

4. Histone coding and its compounding influence on gene expression

5. microRNA as a tool for gene regulation

6. RNA editing and genetic influence

7. Epitranscription: Scope and engineering ability

Part II GLOBAL EPIGENETIC EDITING

8. Global epigenetic editing uses methods of DNA methylation alteration drugs

9. Regulating DNA methylation for developmental disorders

10. Histone modification drug the HDACi: Selectivity and promise

11. Histone modification in cancer treatment

12. Alteration of DNA Methylation in gastric cancer

13. Epigenetic therapy for the treatment of epithelial ovarian cancer

14. Epigenetic application on allergy treatment

15. HDACi therapy for the treatment of depression

16. Histone modification on neurodevelopmental and neuropsychiatric disorders

17. Epigenetics and Addiction

18. Epigenetic Treatment of Persistent Viral Infections

19. MicroRNA as strategy of gene regulation

Part III SITE SPECIFIC EPIGENETIC EDITING

20. Strategy and Molecular tools for site-specific editing

21. Site-specific recruitment of epigenetic factors for spatio-temporal epigenetic editing.

22. Monitoring CRISPR-Cas9 mediated DNA-methylation-editing

23. Locus-specific editing of histone modifications

24. Functional DNA methylation and epigenetic editing on proneuron genes during neuroglial differentiation

25. Epigenetic editing through regulating CRISPR-Cas9 mediated non-coding RNA

26. Epigenetic editing targeting a parkinsonian gene

27. Cancer gene epigenetic editing

28. Epigenetic editing to unveil epigenetic mechanism of breast cancer

29. Editing DNA Methylation on Fragile X syndrome

30. Can RNA editing be engineered?

31. Genetic and epigenetic interactive approaches

Part IV TRANSLATIONAL AND CLINIC APPLICATION

32. Tuning DNA methylation in treating breast cancer:

33. Imminent Epigenetic editing in cancer treatment

34. Epigenetic editing for developmental disorders

35. Epigenetic editing on genetic imprinting

36. Prospective epigenetic treatment on Neurological disease

37. Epigenetic alterations and personalized treatment in cancer

Part V CLOSING VIEW

38. Obstacles and prospective of changing epigenetic codes

39. Ethical matters in modification of epigenetic codes

40. Future epigenetic treatment

Feng C Zhou

Dr. Feng C. Zhou is Professor Emertus of Anatomy and Cell Biology at Indiana University School of Medicine, Indianapolis, Indiana. In his research, Dr. Zhou studies genetic contributions to gene expression that underpin the neurochemical and neuroanatomical differences contributing to alcohol addiction. His previous research has demonstrated that alcohol alters expression cohorts of neural specification genes, and cell cycling genes in the canonical developmental pathways. In recent years, Dr. Zhou has expanded his research to include the genomics and epigenetics of alcoholism, epigenetic editing by optogenetics, cell-wide DNA de-methylation and re-methylation of purkinje neurons in the developing cerebellum, and environmental alterations of epigenetics prior to the birth, among other topics. Dr. Zhou has published widely in scientific, peer reviewed journals including Scientific Reports, PLoS ONE, Oncotarget, Frontiers in Genetics, Brain Research, Cell Transplantation, and Alcohol.

Affiliations and expertise

Professor of Anatomy, Cell Biology, Neuroscience, and Psychology, Emeritus; Adjunct Professor of Behavioral Psychology, Northwestern University, Indianapolis, IN, USA

Trygve Tollefsbol

Dr. Tollefsbol is a Distinguished Professor of Biology and a Senior Scientist in the O’Neal Comprehensive Cancer Center, Integrative Center for Aging Research, Nutrition Obesity Research Center, University Wide Microbiome Center, and the Comprehensive Diabetes Center at the University of Alabama at Birmingham (UAB). He is Director of the UAB Cell Senescence Culture Facility which he established in 1999. Dr. Tollefsbol trained as a Postdoctoral Fellow and Assistant Research Professor with members of the National Academy of Science at Duke University and the University of North Carolina. He earned doctorates in molecular biology and osteopathic medicine from the University of North Texas Health Sciences Center and his bachelor’s degree in Biology from the University of Houston. He has received prior funding from the NCI, NHLBI, NIMH and other federal institutes as well as the Glenn Foundation for Medical Research, Susan G. Komen for the Cure, the American Federation for Aging Research (AFAR), and the American Institute for Cancer Research (AICR) among many other sources.

Affiliations and expertise

Distinguished Professor of Biology Senior Scientist, O’Neal Comprehensive Cancer Center Senior Scientist, Integrative Center for Aging Research Senior Scientist, Comprehensive Diabetes Center Senior Scientist, Nutrition Obesity Research Center Senior Scientist, University Wide Microbiome Center Director, Cell Senescence Culture Facility University of Alabama at Birmingham, AL, USA